According to its SEC 13F filed on Nov 16, 2026, VR Adviser reported 32 long positions worth $2.06B as of Sep 30, 2026. ORKA is 16.8% of the portfolio and the top 10 holdings are 71%. Against Q2 2026 it opened 4 new positions, added to 6, trimmed 5 and exited 4. 9 holdings have a dated FDA decision or data readout in the next 90 days, and 6 more expect one in a stated window such as "H2 2026".
Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval
7 more with a subscription
Full lists with a subscription
13F value by quarter, Q1 2021 to Q3 2026
By company stage (share of value)
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
INM | INMED PHARMACEUTICALS INC | 133.38 K | 181.39 K | 0 | Added +308% | Clinical | None in 90 days | ||
VRDN | VIRIDIAN THERAPEUTICS INC | 3.26 M | 67.08 M | 3.3 | Unchanged | Commercial | Expected Q4 2026 IND Submission | ||
SRZN | SURROZEN INC | 632.93 K | 20.37 M | 1 | Unchanged | Clinical | None in 90 days | ||
MAZE | MAZE THERAPEUTICS INC | 1.55 M | 42.01 M | 2 | Trimmed -4% | Clinical | None in 90 days | ||
KRSA | KORSANA BIOSCIENCES INC | 4.55 M | 145.59 M | 7.1 | New | — | Nov 18, 2026 Pre-clinical data presentation | ||
ENTX | ENTERA BIO LTD | 5.11 M | 14.86 M | 0.7 | New | Clinical | None in 90 days |
Size = share of the portfolio. Option positions show CALL or PUT.
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
32 stocks worth $2.06B at Sep 30, 2026, as reported in its 13F, led by ORKA (16.8% of the portfolio). The full list is in the Holdings table above.
Against Q2 2026: 4 new positions, 6 increases, 5 reductions and 4 full exits, from its 13F filings.
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q4 2026) is due Feb 16, 2027.
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by VR Adviser, LLC, accession 0001615982-26-000019, filed Nov 16, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.